Keros Therapeutics is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need.
Its protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes (MDS) and myelofibrosis. Its lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from iron imbalance.
Its third product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension (PAH), and for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta. Its KER-050 is an engineered ligand trap comprised of a modified ligand-binding domain of the transforming growth factor-beta (TGF-B) receptor.